CAAS Capital Management’s Pfizer PFE Stock Holding History

CAAS Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,300	Closed	-$297K	–	623
2023 Q4	$297K	Buy	+10,300	New	+$311K	0.03%	323
2023 Q2	–	Sell	-13,500	Closed	-$551K	–	811
2023 Q1	$551K	Buy	+13,500	New	+$583K	0.03%	378
2022 Q3	–	Sell	-56,200	Closed	-$2.95M	–	967
2022 Q2	$2.95M	Buy	56,200 +52,300	+1,341%	+$2.67M	0.15%	173
2022 Q1	$202K	Sell	3,900 -107,800	-97%	-$5.59M	0.01%	455
2021 Q4	$6.6M	Buy	+111,700	New	+$5.53M	0.16%	149
2020 Q4	–	Sell	-1,476	Closed	-$51K	–	903
2020 Q3	$51K	Hold	1,476	–	–	﹤0.01%	462
2020 Q2	$46K	Buy	+1,476	New	+$50.1K	﹤0.01%	394

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

CAAS Capital Management's PFE Position: Q1 2024 in Review

CAAS Capital Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 3,900 shares — an estimated $112K sold.

CAAS Capital Management first reported a position in PFE in Q2 2020 and held it in 4 quarters. The position peaked at $991K in Q2 2022. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

CAAS Capital Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
CAAS Capital Management sold 3,900 Pfizer shares in Q1 2024, an estimated $112K.
CAAS Capital Management first reported a position in Pfizer in Q2 2020 and held it in 4 quarters.
CAAS Capital Management's Pfizer position peaked at $991K in Q2 2022.
2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on CAAS Capital Management's 13F filing for Q1 2024, filed 26 Apr 2024.